To include your compound in the COVID-19 Resource Center, submit it here.

Same old story

Commentary

Same old story

If venture capital firms are truly revamping their company startup models, the message of change in the industry doesn't seem to have seeped through to the startups themselves.

At the recent meeting of the Oxford BioScience Partners/Ernst & Young National Conference on Biotechnology Ventures, we were struck by the bland uninformativeness of the vast majority of the presentations we heard. With

Read the full 651 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE